Day 2 Welcomes & Opening Remarks
Contact
As living technologies proliferate, how do we ensure that communities—diverse socioeconomically, culturally, and creatively—are able to not only experience its benefits, but are also active participants and agents of change? What are some of the key elements that are enabling the expansion of biotechnology’s reach beyond ‘traditional’ academic, government, and corporate laboratories?
In this talk Professor David Kong will explore the growth of biotechnology in non-traditional spaces and the creative ecosystem that supports them, including open tools, virtual infrastructure for sharing, and new programs for learning and education. In addition he will share advances in open hardware, including the application of advanced digital fabrication technology to the production of bio-hardware. From ‘Metafluidics,’ to ‘How to Grow (Almost) Anything,’ a distributed biotechnology course that is helping to augment the existing network of over one thousand Fab Labs worldwide with community biology labs, to organizing the first ‘Global Community Biology Summit,’
Â
Innovation in Manufacturing Biomedicines: From New Modalities to Scalable, Accessible Therapeutics Stacy Springs Executive Director, MIT Center for Biomedical Innovation (CBI)
Biologic medicines (e.g., monoclonal antibodies, gene and cell therapies, vaccines) are critical to treating and preventing disease. Recent regulatory approvals of exciting new biomedicines such as cell and gene therapies provide new hope to patients who have exhausted alternative therapies or suffer from a rare disease with no other treatment. To help patients access these medicines, biopharmaceutical companies must be able to manufacture very complex molecules safely, reliably, and in the quantities needed, which can range from the very large (industrialized) scale to the very small (personalized) scale. This presentation will review the challenges in manufacturing these complex biologic medicines as well as approaches to modernization of biomanufacturing with the goal of providing broadened access to biologic medicines. Dr. Springs will describe multiple approaches that MIT’s  Center for Biomedical Innovation and collaborators are taking to achieve this goal, including continuous manufacturing, novel purification strategies, novel analytical technologies for assessing novel product quality attributes, and rapid methods for sterility and viral safety assessment.